Industry committee  Yes.

Industry committee  It is our intention to proceed with the National Research Council and with the strategic innovation fund to invite them to participate in sponsorships of phase two and phase three clinical trials. However, that is not necessary for us to proceed.

Industry committee  Thank you for the question. With the Northern RNA and the Emergent BioSolutions facilities, we have the capacity, beginning in July, to produce 50,000 vials a day. Each vial contains 10 doses of the vaccine. That is half a million doses per day beginning in July. The total capa

Industry committee  As of December 31, 2020, Providence had received $878,182 from NRC and $350,000 from NGen. Thus far in 2021, we have received an additional $907,648 from the NRC. All told, Providence has received just over $2 million, cumulatively and as of today, from the federal government.

Industry committee  No.

Industry committee  That is a commitment through the National Research Council. I just articulated how much we have received of that commitment to date.

Industry committee  That was committed through the National Research Council. That is correct.

Industry committee  It would be important as Health Canada continues to review additional technologies—and not just Providence's—that they have the resources at their disposal to be able to review those technologies on a rolling basis.

Industry committee  Quite frankly, that's beyond my expertise to advise.

Industry committee  I'll give that some consideration and provide some follow-up.

Industry committee  Yes, that is what's been reported in the literature.

Industry committee  Yes. Again, if you're looking at reported data, the messenger RNA vaccines are responding to the variants the quickest.

Industry committee  The adenoviruses are not effective against the variants. They also have a challenge because of the vector delivery system. They have to adapt to the actual design of the vaccine itself and the delivery system in order to accommodate, so they are going to be slow to respond.

Industry committee  The mRNA vaccines have the ability to be redosed, so they do not have that same challenge as the viral vector deliveries.

Industry committee  Absolutely.